CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
0
Authors
Inger Nijhof
Inger Nijhof•Tineke Casneuf•Niels Donk
Published
June 16, 2016
Abstract
Key Points Response to the CD38-targeting antibody daratumumab is significantly associated with CD38 expression levels on the tumor cells. Resistance to daratumumab is accompanied by increased expression of complement-inhibitory proteins.
